Godt nytår og tak for al den viden der deles, her på siden..

]]>https://dev.proinvestor.com/forum/topic/399204/genmab-januar-2026RSS for NodeSun, 07 Jun 2026 16:34:57 GMTThu, 01 Jan 2026 07:33:54 GMT60The collective assessment of analysts
points to an estimated 'Net Revenue- Epkinly- International' of $48.50 million. --U.S' will reach $26.75 million. https://ca.finance.yahoo.com/news/stay-ahead-game-abbvie-abbv-141510153.html

]]>https://dev.proinvestor.com/forum/post/7686285https://dev.proinvestor.com/forum/post/7686285Sat, 31 Jan 2026 10:52:06 GMTDet er vel også en “stille periode” op til regnskab.

]]>https://dev.proinvestor.com/forum/post/7686283https://dev.proinvestor.com/forum/post/7686283Fri, 30 Jan 2026 18:10:32 GMTVi må i sandhed også sige det er en tavs og usynlig ledelse Genmab har anskaffet sig….

]]>https://dev.proinvestor.com/forum/post/7686287https://dev.proinvestor.com/forum/post/7686287Fri, 30 Jan 2026 15:32:19 GMTJa det blev det. Hvorfor er der ingen der ved, måske

]]>https://dev.proinvestor.com/forum/post/7686282https://dev.proinvestor.com/forum/post/7686282Fri, 30 Jan 2026 15:08:00 GMTBlev der handlet
en del aktier hen mod luk ???

]]>https://dev.proinvestor.com/forum/post/7686289https://dev.proinvestor.com/forum/post/7686289Fri, 30 Jan 2026 15:04:09 GMTEGFR x cMet - The line-up is revealed to include Merck & Co and J&J itself. https://www.oncologypipeline.com/apexonco/node/1874

]]>https://dev.proinvestor.com/forum/post/7686279https://dev.proinvestor.com/forum/post/7686279Thu, 29 Jan 2026 15:32:29 GMTRoche FY 2025 CHF: Ocrevus 7,010 (Q4 25 1,688), Columvi 288 , Lunsumio 114

]]>https://dev.proinvestor.com/forum/post/7686288https://dev.proinvestor.com/forum/post/7686288Thu, 29 Jan 2026 06:18:20 GMTBut: "Other expansion cohorts may be considered for monotherapy or combination treatment in the future."

]]>https://dev.proinvestor.com/forum/post/7686277https://dev.proinvestor.com/forum/post/7686277Wed, 28 Jan 2026 14:09:15 GMTI think they just had forgotten to mention this as an included condition as Esophageal Cancer is also mentioned as a closed arm. Thay have added the info that "Enrollment is currently being explored in mCRC (RAS/RAF wild type) patients in the 3L/4L/5L" (i.e.metastatic colorectal cancer). All other arms seem to be closed.

]]>https://dev.proinvestor.com/forum/post/7686281https://dev.proinvestor.com/forum/post/7686281Wed, 28 Jan 2026 14:07:29 GMTan extra arm in the original Petosemtamab trial for Colorectal Cancer with FOLFOX chemo https://clinicaltrials.gov/study/NCT03526835?tab=history&a=6&b=7#version-content-panel they now also mention Esophageal Cancer separately from
Gastroesophageal-junction Cancer

]]>https://dev.proinvestor.com/forum/post/7686286https://dev.proinvestor.com/forum/post/7686286Wed, 28 Jan 2026 13:40:21 GMTH.C. Wainwright has reiterated a Buy rating and $39.00 price target on Genmab A/S (NASDAQ:GMAB) following FDA approval of DARZALEX FASPRO for newly-diagnosed multiple myeloma patients.
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-genmab-stock-at-39-price-target-93CH-4469885

]]>https://dev.proinvestor.com/forum/post/7686280https://dev.proinvestor.com/forum/post/7686280Wed, 28 Jan 2026 12:01:53 GMTon the EGFR x cMet crowded space - Two more companies try to outdo Rybrevant https://www.oncologypipeline.com/apexonco/two-more-companies-try-outdo-rybrevant

]]>https://dev.proinvestor.com/forum/post/7686284https://dev.proinvestor.com/forum/post/7686284Wed, 28 Jan 2026 08:25:00 GMTEnig. En hurtig gevinsthjemtagning og mulighed for supplering, når den ryger tilpas ned i bunden af kanalen (igen-igen).

]]>https://dev.proinvestor.com/forum/post/7686276https://dev.proinvestor.com/forum/post/7686276Wed, 28 Jan 2026 08:00:23 GMTVi har set dette scenarie så mange gange efterhånden. Så absolut ingen overraskelse her. - aktien er styret og absolut ikke modtagelig for TA

]]>https://dev.proinvestor.com/forum/post/7686273https://dev.proinvestor.com/forum/post/7686273Wed, 28 Jan 2026 07:58:54 GMThar du de fire første tal til
aftenens trækning?

]]>https://dev.proinvestor.com/forum/post/7686272https://dev.proinvestor.com/forum/post/7686272Wed, 28 Jan 2026 07:32:55 GMTTror jeg dropper aktier og går over til Lotto. Lotto virker mere forudsigeligt.

]]>https://dev.proinvestor.com/forum/post/7686278https://dev.proinvestor.com/forum/post/7686278Wed, 28 Jan 2026 07:30:04 GMThvad er dagens problem?

]]>https://dev.proinvestor.com/forum/post/7686270https://dev.proinvestor.com/forum/post/7686270Wed, 28 Jan 2026 07:21:08 GMTGenmabs Darzalex Faspro godkendt til kombinationsbehandling af myelomatose https://proinvestor.com/investornyt/1407741/genmabs-darzalex-faspro-godkendt-til-kombinationsbehandling-af-myelomatose

]]>https://dev.proinvestor.com/forum/post/7686275https://dev.proinvestor.com/forum/post/7686275Wed, 28 Jan 2026 04:51:23 GMTTak E L:-)

]]>https://dev.proinvestor.com/forum/post/7686267https://dev.proinvestor.com/forum/post/7686267Tue, 27 Jan 2026 19:16:49 GMTFDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly

]]>https://dev.proinvestor.com/forum/post/7686268https://dev.proinvestor.com/forum/post/7686268Tue, 27 Jan 2026 19:15:47 GMTHope they will tell something about it along with the annual report.

]]>https://dev.proinvestor.com/forum/post/7686274https://dev.proinvestor.com/forum/post/7686274Tue, 27 Jan 2026 17:35:54 GMTCould very well be it.

]]>https://dev.proinvestor.com/forum/post/7686266https://dev.proinvestor.com/forum/post/7686266Tue, 27 Jan 2026 17:33:24 GMTFor me the most interesting is that they just opened a new Petosemtamab trial in NSCLC. We have not seen NSCLC data in public yet i believe, but Genmab will have seen it. Timing coincides. My best guess at this moment would be that Genmab goes with Peto for lung cancer.

]]>https://dev.proinvestor.com/forum/post/7686271https://dev.proinvestor.com/forum/post/7686271Tue, 27 Jan 2026 17:29:49 GMTEGFR x c-MET is already a crowded space and Genmab now also have MCLA-129 from Merus, an EGFRxc-MET Biclonics. Not sure they are going to keep that one, as the tox profile is not great, but it is a large trial that has been going since 2021, so i think we can expect a decision soon after Genmab fully takes control at Merus.

]]>https://dev.proinvestor.com/forum/post/7686265https://dev.proinvestor.com/forum/post/7686265Tue, 27 Jan 2026 17:28:58 GMT